high-throughput solutions for vaccine R&D based on ELISA

Vaccination is one of the most important and economic tools to protect the community from infectious diseases. There are about 60% of the population were fully vaccinated around the world, however, as the virus mutates continuously, the increasingly strong transmission and immune escape capabilities of the mutant strains have brought great challenges to the prevention and control of the epidemic. The emergence of many breakthrough infection cases represents that the "immune barrier" created by vaccination against the wild-type strain of COVID-19 may be flawed. Therefore we urgently need next-generation vaccines that still have high protective efficacy against mutant strains.

As the world experiences a new wave of outbreaks due to the emergence of the Omicron variant, vaccine manufacturers have already stepped up for the development of vaccines against new variants. Earlier, Moderna and Pfizer had announced to start the research on candidate vaccines against Delta and Omicron variants. In China, the China Center for Disease Control and Prevention, Sinovac and Sinopharm Group received the Omicron variant virus isolated by HKU and began their work. In addition, CanSino Bio said they were also working on the development of a new vaccine against the Omicron variant.

In order to support and regulate the development of COVID-19 vaccines, the Food and Drug Administration (FDA) issued the "Development and Licensure of Vaccines to Prevent COVID-19" to determine key indicators for monitoring the whole process of vaccine development.

>>> click to download the Development and Licensure of Vaccines to Prevent COVID-19

ACROBiosystems has undergone methodological validation and independently developed a series of COVID-19-related ELISA kits according to the application as described in the guidelines, aiming to provide comprehensive solutions ranging from quality control of vaccine production to preclinical and clinical research.